Carolyn Wang

#VirBiotechnology News: We announced positive updated Phase 1 data results for our PSMA-targeting, dual-masked #TCE VIR-5500 in participants with metastatic castration-resistant prostate cancer #mCRPC. Learn more in the replay of our conference call ➡️ bit.ly/4tefwtZ

#VirBiotechnology News: We are proud to announce a global strategic collaboration with Astellas Pharma to advance our PSMA-targeting dual-masked T-cell engager #TCE VIR-5500 for the treatment of prostate cancer.➡️ bit.ly/4sbdI3K

Bernie Sanders and AOC do a joint video explaining their view of the shutdown.

We have people in power making broad claims around certain drugs and autism that have been continuously disproven. The degree to which those comments can undermine public health, do harm to women who are pregnant, create anxiety for parents who do have children who are autistic – is violence against the truth.

@chrissyfarr @ShelbyJLiv Congrats, Chrissy! So exciting!

SOME PERSONAL NEWS FRIENDS. And @ShelbyJLiv has the scoop 👇 x.com/ShelbyJLiv/sta…

I'm on a call tonight called White Women: #AnswerTheCall2024 in support of Kamala. First off, there's a lot of us white women on this call... I cannot imagine what is happening over at @Zoom offices right now. I hope someone is delivering them food and liquids. You rock @Zoom!

Ultragenyx $RARE gene therapy for rare liver ailment succeeds in late-stage trial statnews.com/2024/05/30/ult… via @Jasonmmast

@maxonwifi @endpts Congrats to Max and Endpoints!

On Friday (5/31) I start a new chapter as a pharma reporter for @endpts. I have long admired this publication + the stellar reporters there and am stoked to join. As I've told a few people, I loved competing against Endpoints. But I'm even more excited to contribute. LET'S GO!

Come and knock on our door, Joyce DeWitt and Priscilla Barnes! It was a Three's Company reunion at our Evening from the Heart event and @gma captured it: abcnews.go.com/GMA/Culture/th… #AortaEd #AortaSupporta #AorticDissection

Thank you to Kaley Cuoco and the rest of the 8 Simple Rules family for supporting our Evening from the Heart last week! Kaley discusses one of her favorite memories of John with @people: people.com/kaley-cuoco-ho… #AortaEd #AortaSupporta #AorticDissection

@rtrhelp I just signed up for membership yesterday and would like to cancel payment. I wasn't able to find anything I wanted to rent with the subscription, and will do one-off instead. My email is carolynwangchung@gmail.com

At #WorldOrphanUSA, our CEO, Dr. Emil Kakkis, will take the stage to deliver a keynote presentation on using biomarkers for #RareDiseases. Nicole Miller, VP of Molecular Diagnostics, will also take part in a panel on #NewbornScreening and the future for rare disease. More below.

Company News: @ultragenyx's Emil Kakkis on this week's Angelman syndrome data, rare disease treatment modalities, and more. Full video: biotechtv.com/post/ultrageny…

Ultragenyx reports early success with Angelman syndrome drug, backing up 2022 acquisition statnews.com/2024/04/15/ult… via @ADeAngelis_bio for @statnews

@keithdunn @JasminKParis YASSSSS

Jasmin Paris @JasminKParis finished loop five of the #BM100 in 59:58:21.

This workshop w/ participation from @US_FDA will drive an important discussion on applying the Accelerated Approval pathway for #rarediseases and will focus on #Sanfilippo Syndrome. There are a number of novel treatments on the line and many lives at stake. @ultragenyx

"There are so many rare diseases that have no treatments at all," says @ultragenyx CEO Dr. Emil Kakkis, who says his company has been working to improve the process for the latest precision gene therapies, and is hopeful the FDA may use accelerated approvals for treatment.

Today at the North America Rare Disease Summit 2023 (#NARDS), Ultragenyx team member Lisa Kahlman, executive director, public policy & public affairs, interviewed Dr. Peter Marks on his view of leveraging the Accelerated Approval pathway in #RareDisease.

I love the Dr. Peter Marks @US_FDA truth bombs, and there were many today at #NARDS. We're closing on a good one: "Genomic medicine is here to stay. It's about [what country] will get the components together first to make it possible." (here with @Penn ODC Dir. James Wilson, MD)

Ultragenyx announces new data from the investigative Phase 2/3 Orbit study of setrusumab (UX143) in #OsteogenesisImperfecta (OI) at #ASBMR23. Learn more: ultragenyx.co/3txZhxA